½ÃÀ庸°í¼­
»óǰÄÚµå
1495568

¼¼°èÀÇ ¼ÒÇÁÆ® ¹Ì½ºÆ® ÈíÀԱ⠽ÃÀå : Á¦Ç° À¯Çüº°, ¿¬·ÉÃþº°, ¿ëµµº°, À¯Åë ä³Îº°, ÃÖÁ¾ ¿ëµµº° ¿¹Ãø(2024-2032³â)

Soft Mist Inhalers Market - By Product Type (Disposable, Reusable), Age-Group (Adult, Pediatric), Application (Asthma, COPD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use & Global Forecast, 2024 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼ÒÇÁÆ® ¹Ì½ºÆ® ÈíÀԱ⠽ÃÀå ±Ô¸ð´Â õ½Ä, ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD), ¾Ë·¹¸£±â¼º ºñ¿° µî È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ °ßÀεǾî 2024³âºÎÅÍ 2032³â »çÀÌ¿¡ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

WHO¿¡ µû¸£¸é ¸¸¼º Æó»ö¼º ÆóÁúȯ(COPD)Àº ÀÚÁÖ ¹ß»ýÇÏ´Â Æó ÁúȯÀ¸·Î È£Èí°ï¶õ¿¡ ºüÁ® ¿¬°£ 300¸¸ ¸í ÀÌ»óÀÇ »ý¸íÀ» »©¾Ñ°í ÀÖ½À´Ï´Ù. ¼ÒÇÁÆ® ³×ºæ¶óÀÌÀú´Â ±âÁ¸ÀÇ Á¤·® ÈíÀÔ±â(MDI)³ª µå¶óÀÌ ÆÄ¿ì´õ ÈíÀÔ±â(DPI)¿¡ ºñÇØ »ç¿ëÀÇ ¿ëÀ̼º, Áö¼ÓÀûÀÎ ¾à¹° Àü´Þ, ¼Õ°ú ÆóÀÇ ÇùÁ¶Àå¾Ö À§Çè °¨¼Ò µîÀÇ ÀåÁ¡ÀÌ ÀÖÀ¸¸ç, ȯÀÚ, ƯÈ÷ ³ëÀΰú ¾î¸°ÀÌ¿¡°Ô Á¡Á¡ ÀαⰡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

ÃÖ±Ù Á¦¾àȸ»ç´Â ¾à¹°Ã³¹æ, Àåºñ¼³°è, ÃßÁøÁ¦ ½Ã½ºÅÛÀ» ÃÖÀûÈ­ÇÔÀ¸·Î½á ¼ÒÇÁÆ® ³×ºí¶óÀÌÀúÀÇ È¿À²¼º, ¾ÈÀü¼º, È¿À²¼ºÀ» °³¼±Çϱâ À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ °£ÀÇ ºÎµå·¯¿î ºÐ¹«±âÀÇ Ã¤¿ëÀ» ÃËÁøÇÔÀ¸·Î½á ȯÀÚÀÇ ÄÄÇöóÀ̾𽺸¦ °³¼±Çϰí, ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϰí, Ä¡·á ¼º°ú¸¦ ±Ø´ëÈ­ÇÏ´Â °ÍÀ» ¸ñÇ¥·ÎÇÕ´Ï´Ù.

ÀÏȸ¿ë ÈíÀÔ±â´Â Àç»ç¿ë °¡´ÉÇÑ ÀåÄ¡ÀÇ ¼¼Ã´ ¹× À¯Áö º¸¼öÀÇ Çʿ伺À» ÁÙÀ̸鼭 Æí¸®ÇÔ°ú È޴뼺À» Á¦°øÇÕ´Ï´Ù. ÀÌ ÈíÀÔ±â´Â ¶ÇÇÑ °Ç°­ °ü¸® ȯ°æ¿¡¼­ ±³Â÷ ¿À¿°°ú °¨¿° ÀüÆÄÀÇ À§ÇèÀ» ÁÙÀ̰í ȯÀÚÀÇ ¾ÈÀü°ú °¨¿° Á¦¾î¿¡ ´ëÇÑ ¿ì·Á¸¦ ÇØ°áÇÕ´Ï´Ù.

õ½Ä ¿ëµµÀÇ ¼ÒÇÁÆ® ¹Ì½ºÆ® ÈíÀԱ⠽ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁöÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ 9.4%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°è õ½Ä À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ È¿°úÀûÀÌ°í Æí¸®ÇÑ ÈíÀÔ ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼ÒÇÁÆ® ¹Ì½ºÆ® ÈíÀÔ±â´Â Á¤·® ÈíÀÔ±â(MDI) ¹× °Ç½Ä ºÐ¸» ÈíÀÔ±â(DPI)¿Í °°Àº ±âÁ¸ÀÇ ÈíÀÔ ÀåÄ¡¿¡ ºñÇØ Æó Ä§Âø °³¼±, ¼Õ°ú ÆóÀÇ ÇùÁ¶ ¹®Á¦ ¿ÏÈ­, »ç¿ë ÆíÀǼº µî ÀåÁ¡À» Á¦°øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ºÀº ¼Ò¾Æ¿Í ³ëÀÎÀ» Æ÷ÇÔÇÑ Ãµ½Ä ȯÀÚ¿¡°Ô ƯÈ÷ ÀûÇÕÇÕ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ºÎµå·¯¿î ¹Ì½ºÆ® ÈíÀԱ⠻ê¾÷Àº µµ½ÃÈ­, °øÇØ ¹× ¶óÀÌÇÁ ½ºÅ¸ÀÏ º¯È­·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.9%·Î ÇöÀúÇÑ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹°ú Àεµ¿Í °°Àº ½ÅÈï ±¹°¡¿¡¼­´Â ÀÇ·áºñ Áõ°¡¿Í ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»óÀ» º¼ ¼ö ÀÖ½À´Ï´Ù. °Ç°­ °ü¸® ÀÎÇÁ¶óÀÇ ±Þ¼ÓÇÑ Áøº¸´Â È£Èí±âÀÇ °Ç°­°ú Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ÇÔ²²ÀÌ Áö¿ª ½ÃÀå ¼ºÀå¿¡ ´õ¿í ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ¹ÌÄ¡´Â ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • È£Èí±â ÁúȯÀÇ À¯º´·üÀÇ »ó½Â
      • ÈíÀÔ¿ä¹ýÀ» ¼±È£Çϴ ȯÀÚÀÇ ±ÞÁõ
      • ¾à¹°Àü´Þ µð¹ÙÀ̽º¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© ¹× °úÁ¦
      • ³ôÀº ºñ¿ë°ú ´ëü Á¦Ç°ÀÇ °¡¿ë¼º
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • Á¦Ç° ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • »óȯ ½Ã³ª¸®¿À
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ

Á¦4Àå °æÀï ±¸µµ

  • ¼Ò°³
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ÀÏȸ¿ë
  • Àç»ç¿ë °¡´É

Á¦6Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿¬·ÉÃþº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ¼ºÀÎ
  • ¼Ò¾Æ

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¿ëµµº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • õ½Ä
  • COPD(¸¸¼º Æó»ö¼º ÆóÁúȯ)

Á¦8Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : À¯Åë ä³Îº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¹× Áø·á¼Ò
  • ÀçÅÃÄ¡·áÀÇ ÇöÀå
  • ±âŸ ÃÖÁ¾ »ç¿ëÀÚ

Á¦10Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Áö¿ªº°(2021³â-2032³â)

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Aero Pump GmbH
  • Boehringer Ingelheim
  • Changzhou DSB Medical Co., Ltd.
  • Merxin Ltd.
BJH 24.06.25

Soft mist inhalers market size will grow at 9.2% CAGR between 2024 and 2032, driven by the increasing prevalence of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. As per WHO, chronic obstructive pulmonary disease (COPD), a frequent lung ailment, led to breathing difficulties while claiming the lives of over 3 million people annually. Soft nebulizers provide advantages over traditional metered dose inhalers (MDIs) and dry powder inhalers (DPIs), including ease of use, continuous drug delivery, and reduced risk of hand-lung coordination problems, making them increasingly popular with patients, especially the old and children.

Lately, pharmaceutical companies are increasingly investing in R&D activities to improve the effectiveness, safety, and efficiency of soft nebulizers by optimizing drug formulations, device design and propellant systems. These innovations aim to improve patient compliance, minimize side effects and maximize treatment outcomes by promoting the adoption of soft nebulizers among healthcare professionals and patients.

The overall industry is classified into product type, age group, application, distribution channel, end-use, and region.

Based on product type, the soft mist inhalers market from the disposable segment will witness 8.7% growth rate between 2024 and 2032.Disposable inhalers provide convenience and portability while reducing the need for cleaning and maintenance of reusable devices. These inhalers also reduce the risk of cross-contamination and infection transmission in healthcare settings, addressing concerns related to patient safety and infection control.

Soft mist inhalers market from the asthma application is anticipated to witness 9.4% CAGR from 2024 to 2032. The increasing prevalence of asthma worldwide has led to the higher demand for effective and convenient inhalation therapies. Soft mist inhalers provide advantages over traditional inhalation devices, such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), including improved lung deposition, reduced hand-lung coordination issues, and ease of use. These properties are making them particularly suitable for asthma patients, including children and the elderly.

Asia Pacific soft mist inhalers industry is anticipated to grow at a significant pace at 9.9% CAGR over 2024-2032, attributed to urbanization, pollution, and changing lifestyles. There is rising healthcare expenditure and improving access to medical services in emerging economies like China and India. Rapid advancements in healthcare infrastructure, coupled with growing awareness about respiratory health and treatment options will further fuel the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of respiratory conditions
      • 3.2.1.2 Surge in patient preference for inhalation therapy
      • 3.2.1.3 Increasing demand for drug delivery devices
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost and availability of alternative products
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Product pipeline analysis
  • 3.7 Reimbursement scenario
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Disposable
  • 5.3 Reusable

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Adult
  • 6.3 Pediatric

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Asthma
  • 7.3 COPD

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals and clinics
  • 9.3 Homecare settings
  • 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Italy
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 South Africa
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Aero Pump G.m.b.H
  • 11.2 Boehringer Ingelheim
  • 11.3 Changzhou DSB Medical Co., Ltd.
  • 11.4 Merxin Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦